Bifogade filer
PDF
Kurs
-4,41%
Likviditet
0,87 MSEK
Kalender
| Est. tid* | ||
| 2025-11-20 | N/A | Årsstämma |
| 2025-11-14 | 09:00 | Kvartalsrapport 2026-Q1 |
| 2025-08-28 | 08:30 | Bokslutskommuniké 2025 |
| 2025-05-22 | 09:00 | Kvartalsrapport 2025-Q3 |
| 2025-03-11 | - | Extra Bolagsstämma 2025 |
| 2025-02-13 | - | Kvartalsrapport 2025-Q2 |
| 2024-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2024-11-21 | - | Årsstämma |
| 2024-11-15 | - | Kvartalsrapport 2025-Q1 |
| 2024-08-28 | - | Bokslutskommuniké 2024 |
| 2024-05-24 | - | Kvartalsrapport 2024-Q3 |
| 2024-02-22 | - | Kvartalsrapport 2024-Q2 |
| 2023-12-14 | - | Extra Bolagsstämma 2024 |
| 2023-11-24 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2023-11-23 | - | Årsstämma |
| 2023-11-17 | - | Kvartalsrapport 2024-Q1 |
| 2023-08-28 | - | Bokslutskommuniké 2023 |
| 2023-05-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-05-17 | - | Extra Bolagsstämma 2023 |
| 2023-02-23 | - | Kvartalsrapport 2023-Q2 |
| 2022-11-25 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2022-11-24 | - | Årsstämma |
| 2022-11-11 | - | Kvartalsrapport 2023-Q1 |
| 2022-08-26 | - | Bokslutskommuniké 2022 |
| 2022-05-20 | - | Kvartalsrapport 2022-Q3 |
| 2022-02-25 | - | Kvartalsrapport 2022-Q2 |
| 2021-11-26 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2021-11-25 | - | Årsstämma |
| 2021-11-11 | - | Kvartalsrapport 2022-Q1 |
| 2021-08-27 | - | Bokslutskommuniké 2021 |
| 2021-06-17 | - | Extra Bolagsstämma 2022 |
| 2021-05-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-03-02 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Kvartalsrapport 2021-Q2 |
| 2020-11-27 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2020-11-26 | - | Årsstämma |
| 2020-11-12 | - | Kvartalsrapport 2021-Q1 |
| 2020-08-28 | - | Bokslutskommuniké 2020 |
| 2020-05-22 | - | Kvartalsrapport 2020-Q3 |
| 2020-02-28 | - | Kvartalsrapport 2020-Q2 |
| 2019-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2019-11-21 | - | Årsstämma |
| 2019-11-08 | - | Kvartalsrapport 2020-Q1 |
| 2019-08-30 | - | Bokslutskommuniké 2019 |
| 2019-05-17 | - | Kvartalsrapport 2019-Q3 |
| 2019-02-15 | - | Kvartalsrapport 2019-Q2 |
| 2018-11-16 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2018-11-15 | - | Årsstämma |
| 2018-11-09 | - | Kvartalsrapport 2019-Q1 |
| 2018-08-30 | - | Bokslutskommuniké 2018 |
| 2018-05-18 | - | Kvartalsrapport 2018-Q3 |
| 2018-02-16 | - | Kvartalsrapport 2018-Q2 |
| 2017-11-10 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2017-11-09 | - | Årsstämma |
| 2017-11-02 | - | Kvartalsrapport 2018-Q1 |
| 2017-08-18 | - | Bokslutskommuniké 2017 |
| 2017-05-12 | - | Kvartalsrapport 2017-Q3 |
| 2017-02-10 | - | Kvartalsrapport 2017-Q2 |
| 2017-01-19 | - | Extra Bolagsstämma 2018 |
| 2016-11-18 | - | Kvartalsrapport 2017-Q1 |
| 2016-11-11 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
| 2016-11-10 | - | Årsstämma |
| 2016-08-19 | - | Bokslutskommuniké 2016 |
| 2016-05-13 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-12 | - | Kvartalsrapport 2016-Q2 |
| 2015-11-13 | - | Kvartalsrapport 2016-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The Board of Hamlet BioPharma has today decided to appoint Catharina Svanborg as CEO. Catharina immediately assumes the CEO role and continues as a Board member. Martin Erixon leaves the CEO role and will be at the company's disposal during his notice period. Board member Magnus Nylén was appointed by the board as temporary chairman of the board. The board decided to call an extraordinary general meeting to propose Professor Gabriela Godaly to be elected as a new board member and Chairman of the board. Notice will be sent shortly.
Gabriela Godaly is Professor of Clinical microbiology at Lund University and has extensive experience of research and drug development at Lund University and at Gambro Lundia AB.
Professor Godaly is familiar with Hamlet BioPharma and has been actively involved in its development for several years. She served on the Board of Directors of SelectImmune Pharma prior to its merger with Hamlet Pharma.
Professor Godaly is a clinical trials expert, especially in the area of critically ill patients, infectious disease and tuberculosis and her contributions are extremely valuable for the rapidly evolving clinical trials program of Hamlet BioPharma.
This recruitment strengthens the drug development profile of Hamlet BioPharma.
For more information, please contact:
Magnus Nylén
Acting Chairman of the Board
Phone: +46 705759792
E-mail: catharina.svanborg@hamletbiopharma.com
magnus.nylen@partnerfk.se
Catharina Svanborg
CEO
Phone: +46 709 42 65 49
E-mail: catharina.svanborg@hamletbiopharma.com
This disclosure contains information that Hamlet BioPharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-02-2025 15:40 CET.